AHA: Putting a Price on PCSK9 Inhibitor in ACS

(MedPage Today) -- At $13,000 per year, alirocumab still cost-effective for patients with LDL-C 100 mg/dL
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news